Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma.

Multiple myeloma (myeloma) accounts for approximately 12% of all hematologic malignancies and remains incurable despite therapeutic advances.

However, knowledge of targetable tumor antigens, especially neoantigens, is limited.

We applied a mass spectrometry (mass spectrometry)-based immunopeptidomics approach on primary myeloma samples (n = 8) and myeloma cell lines (n = 3), integrating whole-exome and RNA sequencing to comprehensively characterize the myeloma immunopeptidome and systematically search for tumor-associated antigens and neoantigens.